Actinium Pharmaceuticals Inc (STU:7AY1) Stock News, Headlines & Updates
Actinium Pharmaceuticals Inc Stock News from GuruFocus
- 1
- 2
Jun 24, 2025
Actinium Pharma (ATNM) Rating Reaffirmed with Stable Price Target | ATNM Stock News
GuruFocus News • 6:31am
Jun 23, 2025
Innovative Prostate Cancer Treatment ATNM-400 Shows Promising Preclinical Results | ATNM Stock News
GuruFocus News • 12:56pm
Actinium Highlights Expanded Data Set for ATNM-400 in Prostate Cancer Demonstrating Superior Efficacy to Enzalutamide and Ability to Overcome Resistance to ARPI Therapy and PSMA-Ac-225/Lu-177 Labelled
GuruFocus News • 10:46am
Jun 10, 2025
Kuehn Law Encourages Investors of Actinium Pharmaceuticals, Inc. to Contact Law Firm
PRNewswire • 11:00am
May 26, 2025
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Actinium Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - ATNM
PRNewswire • 10:00am
ATNM Deadline: ATNM Investors with Losses in Excess of $100K Have Opportunity to Lead Actinium Pharmaceuticals, Inc. Securities Fraud Lawsuit
PRNewswire • 8:00am
May 23, 2025
Class Action Filed Against Actinium Pharmaceuticals, Inc. (ATNM) - May 27, 2025 Deadline to Join - Contact Levi & Korsinsky
PRNewswire • 5:00am
May 22, 2025
Shareholders that lost money on Actinium Pharmaceuticals, Inc. (ATNM) Urged to Join Class Action -- Contact Levi & Korsinsky to Learn More
Marketwired • 1:00pm
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Actinium
PRNewswire • 10:00am
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 27, 2025 in Actinium Lawsuit - ATNM
PRNewswire • 5:00am
May 21, 2025
ATNM Deadline: ATNM Investors with Losses in Excess of $100K Have Opportunity to Lead Actinium Pharmaceuticals, Inc. Securities Fraud Lawsuit
PRNewswire • 5:00pm
May 20, 2025
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Actinium Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - ATNM
PRNewswire • 9:00am
Investors in Actinium Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before May 27, 2025 to Discuss Your Rights - ATNM
PRNewswire • 5:00am
May 19, 2025
Contact The Gross Law Firm by May 27, 2025 Deadline to Join Class Action Against Actinium Pharmaceuticals, Inc. (ATNM)
PRNewswire • 1:00pm
May 16, 2025
ATNM Investors Have Opportunity to Lead Actinium Pharmaceuticals, Inc. Securities Fraud Lawsuit
PRNewswire • 5:00pm
Investors who lost money on Actinium Pharmaceuticals, Inc.(ATNM) should contact Levi & Korsinsky about pending Class Action - ATNM
Marketwired • 1:00pm
Actinium Pharmaceuticals, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before May 27, 2025 to Discuss Your Rights - ATNM
PRNewswire • 5:00am
May 15, 2025
Class Action Filed Against Actinium Pharmaceuticals, Inc. (ATNM) - May 27, 2025 Deadline to Join - Contact The Gross Law Firm
PRNewswire • 5:00am
May 14, 2025
Kuehn Law Encourages Investors of Actinium Pharmaceuticals, Inc. to Contact Law Firm
Marketwired • 3:00pm
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Actinium
Marketwired • 1:00pm
May 13, 2025
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Actinium Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - ATNM
Marketwired • 8:00am
Levi & Korsinsky Notifies Shareholders of Actinium Pharmaceuticals, Inc.(ATNM) of a Class Action Lawsuit and an Upcoming Deadline
PRNewswire • 5:00am
May 12, 2025
ATNM Investors Have Opportunity to Lead Actinium Pharmaceuticals, Inc. Securities Fraud Lawsuit
PRNewswire • 4:00pm
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Actinium Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - ATNM
PRNewswire • 2:00pm
Shareholders that lost money on Actinium Pharmaceuticals, Inc.(ATNM) Urged to Join Class Action -- Contact The Gross Law Firm to Learn More
Marketwired • 12:00pm
Actinium Pharma (ATNM) Receives Buy Rating with $4.00 Price Target | ATNM Stock News
GuruFocus News • 11:33am
Actinium Pharmaceuticals, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm Before May 27, 2025 to Discuss Your Rights - ATNM
PRNewswire • 5:00am
May 11, 2025
Faruqi & Faruqi Reminds Actinium Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 26, 2025 - ATNM
Marketwired • 9:00am
May 09, 2025
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Actinium Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - ATNM
Marketwired • 7:00am
Levi & Korsinsky Reminds Actinium Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 27, 2025 - ATNM
PRNewswire • 5:00am
May 08, 2025
ATNM LAWSUIT ALERT: Levi & Korsinsky Notifies Actinium Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
Marketwired • 1:00pm
Class Action Filed Against Actinium Pharmaceuticals, Inc. (ATNM) Seeking Recovery for Investors - Contact The Gross Law Firm
PRNewswire • 5:00am
May 07, 2025
The Gross Law Firm Notifies Shareholders of Actinium Pharmaceuticals, Inc. (ATNM) of a Class Action Lawsuit and an Upcoming Deadline
Marketwired • 12:00pm
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Actinium
PRNewswire • 9:00am
May 06, 2025
Actinium Pharmaceuticals (ATNM) Begins Pioneering Iomab-ACT Trial with CAR-T Therapy | ATNM Stock News
GuruFocus News • 8:16am
Actinium Announces Enrollment of First Patient in the Iomab-ACT Commercial CAR-T Trial at the University of Texas Southwestern Medical Center | ATNM Stock News
GuruFocus News • 8:00am
Actinium Announces Enrollment of First Patient in the Iomab-ACT Commercial CAR-T Trial at the University of Texas Southwestern Medical Center
PRNewswire • 8:00am
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Actinium Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - ATNM
PRNewswire • 8:00am
- 1
- 2
Show
Entries
Headlines
Total 0- 1
No recent news